Méndez-Sánchez, N.; Coronel-Castillo, C.E.; Ordoñez-Vázquez, A.L. Current Therapies for Cholestatic Diseases. Biomedicines2023, 11, 1713.
Méndez-Sánchez, N.; Coronel-Castillo, C.E.; Ordoñez-Vázquez, A.L. Current Therapies for Cholestatic Diseases. Biomedicines 2023, 11, 1713.
Méndez-Sánchez, N.; Coronel-Castillo, C.E.; Ordoñez-Vázquez, A.L. Current Therapies for Cholestatic Diseases. Biomedicines2023, 11, 1713.
Méndez-Sánchez, N.; Coronel-Castillo, C.E.; Ordoñez-Vázquez, A.L. Current Therapies for Cholestatic Diseases. Biomedicines 2023, 11, 1713.
Abstract
Cholestasis is a condition defined as an abnormal decrease of bile flow due to progressive pathological states or cholestatic liver diseases that affect the biliary tree at intrahepatic and extrahepatic level. It induces complications such as cirrhosis, liver failure, malignancies, pruritus, fatigue, bone disease and nutritional deficiencies that merit close follow-up and specific interventions to improve quality of life. Furthermore, cholestasis can progress to end-stage liver disease and represents an entity with high morbidity and mortality; and economic burden, Therefore, it is important that clinicians understand the treatment options for cholestatic liver diseases. This review addresses the pathophysiology of cholangiopathies, a general view of current treatments and their molecular targets, and a specific review of those groups of drugs. The objective is to provide clinicians with an overview of the current treatment of cholangiopathies based on evidence on its efficacy and safety.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
